vorinostat has been researched along with Osteogenic Sarcoma in 10 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Osteosarcoma is the most common primary bone cancer in children and is a highly malignant disease, in which 25% of patients present with metastasis at diagnosis." | 5.43 | Suberanilohydroxamic acid (vorinostat) synergistically enhances the cytotoxicity of doxorubicin and cisplatin in osteosarcoma cell lines. ( Clemens, D; Dirksen, U; Hotfilder, M; Klco-Brosius, S; Pettke, A; Potratz, J; Schaefer, C, 2016) |
| "Osteosarcoma is the most common primary bone cancer in children and is a highly malignant disease, in which 25% of patients present with metastasis at diagnosis." | 1.43 | Suberanilohydroxamic acid (vorinostat) synergistically enhances the cytotoxicity of doxorubicin and cisplatin in osteosarcoma cell lines. ( Clemens, D; Dirksen, U; Hotfilder, M; Klco-Brosius, S; Pettke, A; Potratz, J; Schaefer, C, 2016) |
| "A local cytotoxic therapy in the treatment of osteosarcoma and chondrosarcoma might improve the rate of metastasis and survival of patients." | 1.40 | HDAC inhibitor-loaded bone cement for advanced local treatment of osteosarcoma and chondrosarcoma. ( Becker, M; Eckhard, L; Graf, C; Proschek, D; Rommens, PM; Theobald, M; Tonak, M; Wehler, TC, 2014) |
| "Several cancers, however, fail to respond to TRAIL's antineoplastic effects." | 1.38 | Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation. ( Beck, JF; Becker, S; Grauel, D; Palani, CD; Sonnemann, J; Trommer, N; Wittig, S, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shats, I | 1 |
| Gatza, ML | 1 |
| Liu, B | 1 |
| Angus, SP | 1 |
| You, L | 1 |
| Nevins, JR | 1 |
| Tonak, M | 1 |
| Becker, M | 1 |
| Graf, C | 1 |
| Eckhard, L | 1 |
| Theobald, M | 1 |
| Rommens, PM | 1 |
| Wehler, TC | 1 |
| Proschek, D | 1 |
| Mu, X | 1 |
| Brynien, D | 1 |
| Weiss, KR | 1 |
| Blattmann, C | 3 |
| Oertel, S | 3 |
| Thiemann, M | 3 |
| Dittmar, A | 1 |
| Roth, E | 1 |
| Kulozik, AE | 3 |
| Ehemann, V | 3 |
| Weichert, W | 1 |
| Huber, PE | 2 |
| Stenzinger, A | 1 |
| Debus, J | 3 |
| Pettke, A | 1 |
| Hotfilder, M | 1 |
| Clemens, D | 1 |
| Klco-Brosius, S | 1 |
| Schaefer, C | 1 |
| Potratz, J | 1 |
| Dirksen, U | 1 |
| Murahari, S | 1 |
| Jalkanen, AL | 1 |
| Kulp, SK | 1 |
| Chen, CS | 1 |
| Modiano, JF | 2 |
| London, CA | 1 |
| Kisseberth, WC | 1 |
| Bischof, M | 1 |
| Witt, O | 1 |
| Deubzer, HE | 1 |
| Weber, KJ | 2 |
| Schmezer, P | 1 |
| Zelezny, O | 1 |
| Lopez Perez, R | 1 |
| Sonnemann, J | 1 |
| Trommer, N | 1 |
| Becker, S | 1 |
| Wittig, S | 1 |
| Grauel, D | 1 |
| Palani, CD | 1 |
| Beck, JF | 1 |
| Thayanithy, V | 1 |
| Park, C | 1 |
| Sarver, AL | 1 |
| Kartha, RV | 1 |
| Korpela, DM | 1 |
| Graef, AJ | 1 |
| Steer, CJ | 1 |
| Subramanian, S | 1 |
10 other studies available for vorinostat and Osteogenic Sarcoma
| Article | Year |
|---|---|
FOXO transcription factors control E2F1 transcriptional specificity and apoptotic function.
Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Bone Neoplasms; Breast Neoplasms; Cell Proliferatio | 2013 |
HDAC inhibitor-loaded bone cement for advanced local treatment of osteosarcoma and chondrosarcoma.
Topics: Apoptosis; Biomechanical Phenomena; Bone Cements; Bone Neoplasms; Cell Proliferation; Cells, Culture | 2014 |
The HDAC inhibitor Vorinostat diminishes the in vitro metastatic behavior of Osteosarcoma cells.
Topics: Aldehyde Dehydrogenase 1 Family; Animals; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Prol | 2015 |
Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy.
Topics: Animals; Apoptosis; Bone Neoplasms; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibit | 2015 |
Suberanilohydroxamic acid (vorinostat) synergistically enhances the cytotoxicity of doxorubicin and cisplatin in osteosarcoma cell lines.
Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Neoplasms; Cell Growth | 2016 |
Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.
Topics: Animals; Bone Neoplasms; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dogs; Doxoru | 2017 |
Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition.
Topics: Antigens, Nuclear; Apoptosis; Carrier Proteins; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Rep | 2010 |
Suberoylanilide hydroxamic acid affects γH2AX expression in osteosarcoma, atypical teratoid rhabdoid tumor and normal tissue cell lines after irradiation.
Topics: Cell Line, Tumor; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Histone D | 2012 |
Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation.
Topics: Apoptosis; Bone Neoplasms; Caspase 8; Cell Line, Tumor; Enzyme Activation; Histone Deacetylase Inhib | 2012 |
Combinatorial treatment of DNA and chromatin-modifying drugs cause cell death in human and canine osteosarcoma cell lines.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2012 |